Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMERIDIAN: Dianicline for Smoking Cessation
NCT00387946Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Dianicline with Placebo (2 arms). Primary endpoint: Continuous abstinence from tobacco smoking at 7 weeks. Started Sep 2006; status: completed.
02
Drugs
dianicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00387946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387946.